Want to join the conversation?
For 4Q16, $KORS expects revenue to be $1.13-1.15Bil, which includes about $36MM additional sales due to the 53rd week. Diluted EPS is expected to be $0.93-0.97, assuming 182.5MM shares outstanding. Comp store sales is expected to be flat on a reported basis. $KORS expects foreign currency to impact net income by about $3MM and EPS by about $0.02.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.